Analysis of patient characteristics and safety of insulin glargine U300 use in 21 359 patients with type-2 diabetes and chronic kidney disease: DPV registry study.

4.2 Glargine U300 use and concomitant therapy The dose of Gla‐300 (total and daily) exhibited an increasing trend, peaking at Stage 3, 4 and 5 CKD indicating a potential association between reduced kidney function and insulin requirements.

also in 63,971 other papers

In our analysis a decreasing trend was observed in the usage of concomitant glucose‐lowering therapies with worsening CKD stages, especially from stages 3 to 5.

also in 47,180 other papers